Skip to main content

Market Overview

Mid-Morning Market Update: Markets Mostly Lower; JPMorgan Tops Q2 Views


Following the market opening Tuesday, the Dow traded up 0.15% to 26123.80 while the NASDAQ fell 1.74% to 10210.48. The S&P also fell, dropping 0.55% to 3,137.81.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 3,364,547 cases with around 135,615 deaths. Brazil confirmed a total of over 1,884,967 COVID-19 cases with 72,833 deaths, while India reported a total of at least 906,752 confirmed cases and 23,727 deaths. In total, there were at least 13,113,181 cases of COVID-19 worldwide with over 573,288 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Energy shares rose 1.5% on Tuesday.

In trading on Tuesday, consumer discretionary shares fell 1.8%.

Top Headline

JPMorgan Chase & Co. (NYSE: JPM) reported better-than-expected results for its second quarter.

JPMorgan reported quarterly earnings of $1.38 per share, beating analysts’ estimates of $1.04 per share. The company reported sales of $33.00 billion, exceeding expectations of $30.29 billion.

Equities Trading UP

INmune Bio, Inc. (NASDAQ: INMB) shares shot up 85% to $16.40 following a positive clinical readout from the company. The company released interim results from a Phase 1b study of its lead drug candidate XPro 1595 in Alzheimer's disease, showing the investigational drug reduced neuroinflammation by 40.6% in a brain fiber pathway, which is important for learning and memory.

Shares of Rigel Pharmaceuticals, Inc (NASDAQ: RIGL) got a boost, shooting 83% to $3.955 after the company announced the launch of an investigator-sponsored trial of Fostamatinib for the treatment of COVID-19 pneumonia.

Perceptron, Inc. (NASDAQ: PRCP) shares were also up, gaining 67% to $5.25 after the company received an order from an automotive supplier for its in-line measurement technology.

Equities Trading DOWN

Equillium, Inc. (NASDAQ: EQ) shares tumbled 38% to $16.50 after the company filed a prospectus supplement related to a common stock offering of up to $150 million. Equillium shares jumped more than 730% on Monday after the company announced its clinical trial showed Itolizumab reduced mortality in patients hospitalized with COVID-19.

Shares of WiMi Hologram Cloud Inc. (NASDAQ: WIMI) were down 31% to $16.99. WiMi Hologram Cloud shares jumped 69% on Monday on continued momentum after the company announced its AR+AI Vision will drive a new wave of 5G applications.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) was down, falling 19% to $41.55 after surging 23% on Monday.


In commodity news, oil traded down 0.6% to $39.85, while gold traded down 1.1% to $1,794.20.

Silver traded down 2.6% Tuesday to $19.28, while copper fell 1% to $2.9265.

Euro zone

European shares were lower today. The eurozone’s STOXX 600 fell 1.3%, the Spanish Ibex Index fell 1.2%, while Italy’s FTSE MIB Index declined 1%. Meanwhile, the German DAX 30 dropped 1.5%, French CAC 40 declined 1.7% and UK shares fell 0.3%.


The NFIB small business optimism index rose to 100.6 in June, a 6.2 points rise from May's reading.

US inflation rate rose to 0.6% in June versus May's 0.1%.

The Treasury is set to auction 52-week bills at 11:30 a.m. ET.

Federal Reserve Governor Lael Brainardis set to speak at 2:00 p.m. ET.

Federal Reserve Bank of St. Louis President James Bullard will speak at 2:30 p.m. ET.


Related Articles (EQ + INMB)

View Comments and Join the Discussion!

Posted-In: Earnings News Penny Stocks Eurozone Commodities Global Intraday Update Markets

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at